On Wednesday, Shares of Celator Pharmaceuticals, Inc. (NASDAQ:CPXX), surged 23.66% to $2.77.
Celator Pharmaceuticals, declared final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in the Phase 3 study comparing CPX-351 (cytarabine:daunorubicin) liposome injection to the standard of care regimen, referred to as 7+3 (conventional cytarabine and daunorubicin treatment), in patients with untreated high-risk (secondary) acute myeloid leukemia (AML). The results showed that CPX-351 produced a relative improvement in induction response rate of 43.2% (47.7% for CPX-351 vs. 33.3% for the 7+3 regimen).
Data on overall survival, the primary endpoint, are predictable in the first quarter of 2016. However, induction response rate is a key secondary endpoint in the study and has been an important surrogate of overall survival and clinical benefit in this patient population. These data validate the induction response rates observed in the Phase 2 study, which was associated with a marked improvement in overall survival.
Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, in addition to molecularly targeted agents to deliver improved anti-cancer activity.
Shares of E. I. du Pont de Nemours and Company (NYSE:DD), declined -3.36% to $66.20, during its last trading session.
On June 23, DuPont Pioneer (DuPont) declared a technology license and research partnership agreement with Vilnius University to further the technical and commercial utility of guided Cas9 genome editing technology. Under the agreement, DuPont receives an exclusive license to Vilnius University intellectual property for all commercial uses, counting in agriculture. In addition, Vilnius University and DuPont have reached a multi-year research partnership to advance the development of the technology.
A team of scientists from the Vilnius University Institute of Biotechnology was one of the first groups to discover that the Cas9 protein could be repurposed to precisely edit targeted sections of an organism’s DNA to achieve a specific outcome. In plants, this can comprise promoting drought tolerance and disease resistance for protecting plant health and increasing crop yields.
- I. du Pont de Nemours and Company operates as a science and technology based company worldwide. The company’s Agriculture segment offers corn hybrid, soybean, canola, sunflower, sorghum, inoculants, seed products, wheat, rice, herbicides, fungicides, and insecticides.
Finally, U.S. Bancorp (NYSE:USB), ended its last trade with -0.80% loss, and closed at $44.74.
U.S. Bank has hired Reba Dominski as senior vice president of the U.S. Bank Foundation and Community Relations. Dominski brings a wealth of corporate giving and community relations experience to this role, which oversees the U.S. Bank Foundation and employee volunteerism. Last year, the foundation provided more than $23.5 million in grant funding and employees donated more than 370,000 volunteer hours.
Dominski joins U.S. Bank from Target Corporation, where she spent more than 20 years, counting the past six years as senior director of community relations focused on education. Preceding to this role, Dominski worked within several businesses at Target counting: merchandising, sourcing, stores, and merchandise planning.
Dominski is an active volunteer, presently serving as a member of the national advisory board for Strive Together. She formerly served on the executive committee and leadership council for Generation Next. Dominski has a bachelor’s degree in English from the University of Michigan.
U.S. Bancorp, a financial services holding company, provides a range of financial services in the United States. It offers depository services, which comprise checking accounts, savings accounts, and time certificate contracts; and lending services, such as traditional credit products, in addition to credit card services, leasing, financing and import/export trade, asset-backed lending, agricultural finance, and other products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
